<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562805</url>
  </required_header>
  <id_info>
    <org_study_id>ELX-CL-1806</org_study_id>
    <nct_id>NCT04562805</nct_id>
  </id_info>
  <brief_title>Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)</brief_title>
  <official_title>Infinity-Swedeheart Study: Registry Based Randomized Clinical Trial (R-RCT) Comparing Long Term Outcomes of the DynamX Bioadaptor to the Resolute Onyx Stent in a More-comer PCI Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elixir Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elixir Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized&#xD;
      registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor :&#xD;
      Resolute Onyx).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized&#xD;
      registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor :&#xD;
      Resolute Onyx). 2400 Patients will be randomized in Sweden. Patients will be followed at 30&#xD;
      days and 1 year by phone, and at 6 months and 2 to 5 years through clinical and diagnostic&#xD;
      registries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The patients will be blinded to the assigned device from the point of randomization onward. Study site personnel will be trained not to disclose the treatment assignment to the patient. Site personnel assigned to conduct phone follow-up visits will be provided with a standard interview script in order to reduce bias.&#xD;
The Clinical Event Committee will be blinded to the fullest extent possible with only redacted source documents included in the event packages.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Device Oriented Clinical Endpoint (DOCE) of target lesion failure (TLF; cardiovascular death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>During Study Procedure</time_frame>
    <description>Lesion-Level Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>In-Hospital, assessed up to 7 days</time_frame>
    <description>Patient-Level Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Rate of Device Oriented Clinical Endpoint (DOCE)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Composite Device Oriented Clinical Endpoint (DOCE) (TLF; cardiovascular death, TV-MI, ischemia-driven TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Rate of Patient Oriented Clinical Endpoint (POCE)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Composite Patient Oriented Clinical Endpoint (POCE) (all-cause mortality, any stroke, any myocardial infarction (includes non-target vessel territory) and any revascularization). Note: Stroke to be collected and included in the POCE at 1 year and 5 years only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Target Vessel Failure (TVF)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Target vessel failure (TVF; cardiovascular death, target vessel myocardial infarction (TV-MI), or target vessel revascularization (TVR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Rate of cardiovascular death, any myocardial infarction and any revascularization</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Composite of cardiovascular death, any myocardial infarction and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Ischemia driven target lesion revascularization (ID-TLR)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Ischemia driven target lesion revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>All Target Lesion Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>All Target Vessel Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Ischemia driven target vessel revascularization (ID-TVR)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Ischemia driven target vessel revascularization (ID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Ischemia driven non target vessel revascularization (ID-NTVR)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Ischemia driven non target vessel revascularization (ID-NTVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Non target vessel revascularization (NTVR)</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Non target vessel revascularization (NTVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All revascularization</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>All revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Myocardial Infarction</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>All MI, Q-Wave and Non Q-Wave MI, TV-MI, NTV-MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Death</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Cardiovascular Death, All-Cause Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite: Cardiovascular death or myocardial infarction</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Composite: Cardiovascular death or myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite: All-cause death or myocardial infarction</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Composite: All-cause death or myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite: All-cause death, myocardial infarction or target vessel revascularization</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Composite: All-cause death, myocardial infarction or target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any stroke</measure>
    <time_frame>1 year and 5 years</time_frame>
    <description>Any stroke (collected at 1 year and 5 years only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anginal Status</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Anginal Status by Seattle Angina Questionnaire-7 (SAQ-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Stent Thrombosis</measure>
    <time_frame>30 days, 6 months, 1-5 years</time_frame>
    <description>Composite: Probable or definite stent thrombosis Probable Stent Thrombosis Definite Stent Thrombosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>DynamX Bioadaptor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elixir Medical DynamX™ Sirolimus Eluting Coronary Bioadaptor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medtronic Resolute Onyx Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DynamX Bioadaptor</intervention_name>
    <description>DynamX Bioadaptor Treatment</description>
    <arm_group_label>DynamX Bioadaptor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx</intervention_name>
    <description>Resolute Onyx Treatment</description>
    <arm_group_label>Medtronic Resolute Onyx Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          -  Patient age ≥ 18 and ≤ 85 years&#xD;
&#xD;
          -  Patient understands the trial requirements and treatment procedures and provides&#xD;
             informed consent prior to any trial-specific tests or treatment&#xD;
&#xD;
          -  Patients with CCS (stable angina, chronic angina, and chronic coronary artery disease)&#xD;
             or ACS (unstable angina, ST-elevated myocardial infarction, and non-ST-elevated&#xD;
             myocardial infarction) indicated for a percutaneous intervention with stent&#xD;
             implantation.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          -  Patient has ≤ 3 lesions planned to be treated during the index procedure, each in a&#xD;
             native epicardial vessel (including up to 1 planned Non-Target Lesion).&#xD;
&#xD;
               1. Treatment is limited to a maximum of 2 Target Lesions per epicardial vessel. Any&#xD;
                  planned Non-Target Lesion must be located in a separate vessel from Target&#xD;
                  Lesion(s).&#xD;
&#xD;
               2. When treatment of 2 target lesions in a single epicardial vessel is planned,&#xD;
                  there must be adequate separation between lesions to ensure a gap of greater than&#xD;
                  or equal to 10 mm between study devices.&#xD;
&#xD;
               3. If a planned Non-Target Lesion is present it must have been treated without&#xD;
                  complication* prior to randomization.&#xD;
&#xD;
               4. The definition of epicardial vessels is the LAD, LCx and RCA, and is inclusive of&#xD;
                  their branches.&#xD;
&#xD;
          -  Target Lesion vessel diameter(s) and lesion length(s) suitable for implantation with&#xD;
             either study device (DynamX Bioadaptor or Control) using a single device per lesion.&#xD;
&#xD;
          -  Successful pre-dilatation of a minimum of 1 Target Lesion, defined as no waist in the&#xD;
             inflated pre-dilatation balloon (using two orthogonal views) with a pre-dilatation&#xD;
             balloon diameter size approximately 0.25 mm smaller than reference vessel diameter but&#xD;
             not more than 0.5 mm smaller than the reference vessel diameter. A residual diameter&#xD;
             stenosis prior to study device implantation by visual estimate is recommended to be &lt;&#xD;
             30%.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction with Killip class III and IV&#xD;
&#xD;
          -  Known history of chronic heart failure with LVEF &lt; 30%&#xD;
&#xD;
          -  Life expectancy &lt; 2 years&#xD;
&#xD;
          -  Patients on renal dialysis or with known eGFR &lt; 30 ml/min&#xD;
&#xD;
          -  Planned surgery necessitating interruption of dual antiplatelet therapy within 6&#xD;
             months after the index procedure&#xD;
&#xD;
          -  Known intolerance to components of the study device or control stent or medication&#xD;
             required (e.g. intolerance to concomitant anticoagulation or antiplatelet therapy)&#xD;
&#xD;
          -  Patient has a current diagnosis of active COVID-19 disease&#xD;
&#xD;
          -  Patient is currently participating in another clinical trial with an investigational&#xD;
             device or an investigational drug that has the potential to impact study results (such&#xD;
             as, anti-thrombotic or anti-platelet medications) that has not yet completed its&#xD;
             primary endpoint&#xD;
&#xD;
          -  Known pregnancy or breastfeeding&#xD;
&#xD;
          -  Patient is, in the opinion of the Investigator, unable to comply with the requirements&#xD;
             of the study protocol or is unsuitable for the study for any reason&#xD;
&#xD;
          -  Subject has undergone prior PCI in a target vessel during the last 12 months. (A&#xD;
             target lesion can be randomized and treated if a vessel contains a stent older than 12&#xD;
             months if the stent is more than 10 mm from the intended target lesion.)&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          -  Lesions in the left main artery&#xD;
&#xD;
          -  Venous or arterial bypass grafts&#xD;
&#xD;
          -  In-stent restenosis&#xD;
&#xD;
          -  Chronic total occlusion&#xD;
&#xD;
          -  Ostial lesions (&lt; 3 mm of the ostium of the RCA, LAD or LCx)&#xD;
&#xD;
          -  Prior stent located in a Non-Target Vessel &lt; 48 hours prior to the index procedure&#xD;
&#xD;
          -  Lesion with severe calcification requiring rotablation or atherectomy&#xD;
&#xD;
          -  Bifurcation lesions requiring a planned 2 or more stent technique&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Erlinge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital, Lund</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan James, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Preciado, Ph.D.</last_name>
    <phone>+1-510-333-1437</phone>
    <email>jpreciado@ElixirMedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Candace Elek, M.S.</last_name>
    <phone>+1-408-913-5468</phone>
    <email>celek@elixirmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mälarsjukhuset Eskilstuna</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Hamid, MD</last_name>
    </contact>
    <contact_backup>
      <email>mehmet.hamid@regionsormland.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hallands sjukhus</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Adielsson</last_name>
    </contact>
    <contact_backup>
      <email>martin.adielsson@regionhalland.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helsingborgs lasarett</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Wagner, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <email>henrik.wagner@med.lu.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Blekingesjukhuset i Karlskrona</name>
      <address>
        <city>Karlskrona</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl-Magnus Pripp, MD</last_name>
    </contact>
    <contact_backup>
      <email>carl-magnus.pripp@regionblekinge.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centralsjukhuset Karlstad</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Stalby, MD</last_name>
    </contact>
    <contact_backup>
      <email>per.stalby@regionvarmland.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus i Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Erlinge, MD, PhD</last_name>
      <phone>+46 46 17 25 97</phone>
      <email>david.erlinge@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus i Malmö</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Birgander, MD, PhD</last_name>
      <email>mats.birgander@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capio St Görans sjukhus</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pontus Lindroos, MD</last_name>
    </contact>
    <contact_backup>
      <email>pontus.lindroos@capiostgoran.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Danderyds sjukhus</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattias Törnerud, MD</last_name>
      <email>mattias.tornerud@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Venetsanos, MD, PhD</last_name>
      <email>dimitrios.venetsanos@liu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Böhm, MD, PhD</last_name>
      <email>felix.bohm@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Witt, MD, PhD</last_name>
      <email>nils.witt@sodersjukhuset.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Espen Haugen, MD</last_name>
    </contact>
    <contact_backup>
      <email>espen.haugen@rvn.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunderby sjukhus</name>
      <address>
        <city>Södra Sunderbyn</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Millgård, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <email>jonas.millgard@norrbotten.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Norrlands universitetssjukhus Umeå</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Andersson, MD</last_name>
      <email>jonas.andersson-lindholm@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan James, MD, PhD</last_name>
      <phone>+46-70 5944404</phone>
      <email>Stefan.James@ucr.uu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Västmanlands sjukhus i Västerås</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Grimfjärd, MD, PhD</last_name>
      <email>per.grimfjard@regionvastmanland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Örebro</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Fröbert, MD, PhD</last_name>
      <phone>+46 19 303000</phone>
      <email>ole.frobert@oru.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Östersunds sjukhus</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Ulvenstam, MD, PhD</last_name>
      <email>anders.ulvenstam@jll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

